Literature DB >> 17017987

A first QSAR model for galectin-3 glycomimetic inhibitors based on 3D docked structures.

Suzanne Sirois1, Denis Giguère, René Roy.   

Abstract

This study presents the first QSAR model for Galectin-3 glycomimetic inhibitors based on docked structures to the carbohydrate recognition domain (CRD). Quantitative numerical methods such as PLS (Partial Least Squares) and ANN (Artificial Neural Networks) have been used and compared on QSAR models to establish correlations between molecular properties and binding affinity values (Kd). Training and validation of QSAR predictive models was performed on a master dataset consisting of 136 compounds. The molecular structures and binding affinities (Kd) (136 compounds) were obtained from the literature. To address the issue of dimensionality reduction, molecular descriptors were selected with PLS contingency approach, ANN, PCA (Principal Component Analysis) and GA (Genetic Algorithms) for the best predictive Galectin-3 binding affinity (Kd). Final sets comprising 56, 31 and 35 descriptors were obtained with PLS, PCA and ANN, respectively. The objective of this prototype QSAR model is to serve as a first guideline for the design of novel and potent Gal-3 selective inhibitors with emphasis on modification at both C-3' and at O-3 positions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017987     DOI: 10.2174/157340606778250252

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  6 in total

1.  Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Authors:  Ruud P M Dings; Nigam Kumar; Michelle C Miller; Melissa Loren; Huzaifa Rangwala; Thomas R Hoye; Kevin H Mayo
Journal:  J Pharmacol Exp Ther       Date:  2012-12-11       Impact factor: 4.030

Review 2.  When galectins recognize glycans: from biochemistry to physiology and back again.

Authors:  Santiago Di Lella; Victoria Sundblad; Juan P Cerliani; Carlos M Guardia; Dario A Estrin; Gerardo R Vasta; Gabriel A Rabinovich
Journal:  Biochemistry       Date:  2011-08-26       Impact factor: 3.162

3.  Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Authors:  Ruud P M Dings; Michelle C Miller; Irina Nesmelova; Lucile Astorgues-Xerri; Nigam Kumar; Maria Serova; Xuimei Chen; Eric Raymond; Thomas R Hoye; Kevin H Mayo
Journal:  J Med Chem       Date:  2012-05-30       Impact factor: 7.446

4.  Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models.

Authors:  Nathan A Koonce; Robert J Griffin; Ruud P M Dings
Journal:  Int J Mol Sci       Date:  2017-12-09       Impact factor: 5.923

Review 5.  Galectins as Molecular Targets for Therapeutic Intervention.

Authors:  Ruud P M Dings; Michelle C Miller; Robert J Griffin; Kevin H Mayo
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

6.  Synthesis and solvodynamic diameter measurements of closely related mannodendrimers for the study of multivalent carbohydrate-protein interactions.

Authors:  Yoann M Chabre; Alex Papadopoulos; Alexandre A Arnold; René Roy
Journal:  Beilstein J Org Chem       Date:  2014-07-04       Impact factor: 2.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.